Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study
Acetalax and bisacodyl represent a prospective novel drug mechanism-of-action type, affect mitochondrial function and affect tumor growth in vivo. Their activity may be predicted by TRPM4 but with more accuracy adding other genes in multivariate analysis for triple negative breast cancer (TNBC). Acetalax has a biphasic mean half-life of 5.8 hours.
Authors
- Rania El Botty
- Sudhir Varma (ORCID: https://orcid.org/0000-0002-4096-4782)
- Fathi Elloumi (ORCID: https://orcid.org/0009-0007-7116-508X)
- Augustin Luna (ORCID: https://orcid.org/0000-0001-5709-371X)
- Yanghsin Wang (ORCID: https://orcid.org/0009-0005-3445-3707)
- Yves Pommier (ORCID: https://orcid.org/0000-0002-3108-0758)
- Keyvan Rezaï (ORCID: https://orcid.org/0000-0002-3328-3102)
- Ludivine Morriset
- Elisabetta Marangoni (ORCID: https://orcid.org/0000-0002-3337-6448)
- Samuel Huguet (ORCID: https://orcid.org/0000-0002-6403-9110)
- William C. Reinhold (ORCID: https://orcid.org/0000-0001-5513-9323)
- Rémi Montagne (ORCID: https://orcid.org/0000-0001-9813-3204)
- Makito Mizunuma (ORCID: https://orcid.org/0000-0001-5138-9464)
- Léa Huguet
- Naoko Takebe (ORCID: https://orcid.org/0000-0002-5790-4954)
- Ahmed Dahmani (ORCID: https://orcid.org/0000-0002-8770-120X)
Institutions
- National Institutes of Health (US)
- Inserm (FR)
- Virginia International University (US)
- Université Paris Sciences et Lettres (FR)
- United States National Library of Medicine (US)
- EP Analytics (United States) (US)
- Hôpital René Huguenin (FR)
- National Cancer Institute (US)
- Center for Cancer Research (US)
- ICF International (United States) (US)
- École Nationale Supérieure des Mines de Paris (FR)
- Institut Curie (FR)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0435
- Citations
- 6
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 10.90
Funders
- National Institutes of Health
- National Cancer Institute
- U.S. National Library of Medicine